Recent Advances in Immune-Based Therapies for Type 1 Diabetes

被引:17
作者
Schweiger, Darja Smigoc [1 ,2 ]
机构
[1] Univ Ljubljana, Fac Med, Ljubljana, Slovenia
[2] Univ Childrens Hosp, Univ Med Ctr Ljubljana, Dept Endocrinol Diabet & Metab Dis, Ljubljana, Slovenia
来源
HORMONE RESEARCH IN PAEDIATRICS | 2023年 / 96卷 / 06期
关键词
Type; 1; diabetes; Immunotherapy; Clinical trials; Prevention; Beta-cell preservation; BETA-CELL FUNCTION; ANTI-CD3; MONOCLONAL-ANTIBODY; RABBIT ANTITHYMOCYTE GLOBULIN; B-LYMPHOCYTE DEPLETION; CD4(+)CD25(+) T-CELLS; PRESERVES C-PEPTIDE; RECENT-ONSET; DOUBLE-BLIND; HIGH-RISK; PREVENTION;
D O I
10.1159/000524866
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by progressive destruction of the pancreatic beta cells, leading to a lifelong dependence on insulin. It is associated with an increased morbidity and mortality from diabetes-related complications and a significant treatment burden. However, there has been substantial progress in therapeutic strategies that can affect the course of the disease. Summary: This review addresses advances in immunotherapy aimed at preserving residual beta-cell function in individuals with a recent onset of T1D and arresting the disease in pre-symptomatic stages. Recent and ongoing clinical trials have investigated the efficacy and safety of various immunotherapeutic strategies aimed at targeting several mechanisms of autoimmunity, which are thought to be important in disease pathogenesis, and therapies that also address beta-cell health. So far, T-cell-directed therapies that led to a favourable balance between T-effector cell depletion or modulation and preservation or expansion of regulatory T cells have shown the most success. Furthermore, regarding the timing of intervention, teplizumab was the first immunomodulatory agent to demonstrate a significant delay in disease progression in high-risk individuals before clinical onset. Key Messages: As more targeted immune interventions with potentially fewer side effects are closer to the translation into clinical practice, some new challenges may need to be addressed. The use of combination approaches that include immunotherapeutic strategies targeting different aspects of the immune system and interventions that improve beta-cell health may be required, along with the use of individualized patient-tailored approaches, a move towards early intervention, and a focus on patient-reported outcome measures.
引用
收藏
页码:631 / 645
页数:15
相关论文
共 118 条
  • [1] Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study
    Ambery, P.
    Donner, T. W.
    Biswas, N.
    Donaldson, J.
    Parkin, J.
    Dayan, C. M.
    [J]. DIABETIC MEDICINE, 2014, 31 (04) : 399 - 402
  • [2] Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes
    Aronson, Ronnie
    Gottlieb, Peter A.
    Christiansen, Jens S.
    Donner, Thomas W.
    Bosi, Emanuele
    Bode, Bruce W.
    Pozzilli, Paolo
    [J]. DIABETES CARE, 2014, 37 (10) : 2746 - 2754
  • [3] Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial
    Assfalg, Robin
    Knoop, Jan
    Hoffman, Kristi L.
    Pfirrmann, Markus
    Zapardiel-Gonzalo, Jose Maria
    Hofelich, Anna
    Eugster, Anne
    Weigelt, Marc
    Matzke, Claudia
    Reinhardt, Julia
    Fuchs, Yannick
    Bunk, Melanie
    Weiss, Andreas
    Hippich, Markus
    Halfter, Kathrin
    Hauck, Stefanie M.
    Hasford, Jorg
    Petrosino, Joseph F.
    Achenbach, Peter
    Bonifacio, Ezio
    Ziegler, Anette-Gabriele
    [J]. DIABETOLOGIA, 2021, 64 (05) : 1079 - 1092
  • [4] Type 1 diabetes
    Atkinson, Mark A.
    Eisenbarth, George S.
    Michels, Aaron W.
    [J]. LANCET, 2014, 383 (9911) : 69 - 82
  • [5] Atlas, 2019, IDF DIABETES ATLAS, DOI DOI 1124156/HTTPS://WWW.DIABETESATLAS.ORG/UPLOAD/RESOURCES/MATERIAL/20191218_144459_2019_GLOBAL_FACTSHEET.PDF
  • [6] Antithymocyte globulins in renal transplantation-from lymphocyte depletion to lymphocyte activation: The doubled-edged sword
    Bamoulid, Jamal
    Crepin, Thomas
    Courivaud, Cecile
    Rebibou, Jean-Michel
    Saas, Philippe
    Ducloux, Didier
    [J]. TRANSPLANTATION REVIEWS, 2017, 31 (03) : 180 - 187
  • [7] Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes
    Battaglia, Manuela
    Ahmed, Simi
    Anderson, Mark S.
    Atkinson, Mark A.
    Becker, Dorothy
    Bingley, Polly J.
    Bosi, Emanuele
    Brusko, Todd M.
    DiMeglio, Linda A.
    Evans-Molina, Carmella
    Gitelman, Stephen E.
    Greenbaum, Carla J.
    Gottlieb, Peter A.
    Herold, Kevan C.
    Hessner, Martin J.
    Knip, Mikael
    Jacobsen, Laura
    Krischer, Jeffrey P.
    Long, S. Alice
    Lundgren, Markus
    McKinney, Eoin F.
    Morgan, Noel G.
    Oram, Richard A.
    Pastinen, Tomi
    Peters, Michael C.
    Petrelli, Alessandra
    Qian, Xiaoning
    Redondo, Maria J.
    Roep, Bart O.
    Schatz, Desmond
    Skibinski, David
    Peakman, Mark
    [J]. DIABETES CARE, 2020, 43 (01) : 5 - 12
  • [8] New Insights Into the Role of Autoreactive CD8 T Cells and Cytokines in Human Type 1 Diabetes
    Bender, Christine
    Rajendran, Sakthi
    von Herrath, Matthias G.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2021, 11
  • [9] Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes
    Bingley, Polly J.
    Wherrett, Diane K.
    Shultz, Ann
    Rafkin, Lisa E.
    Atkinson, Mark A.
    Greenbaum, Carla J.
    [J]. DIABETES CARE, 2018, 41 (04) : 653 - 661
  • [10] Type 1 diabetes immunotherapy using polyclonal regulatory T cells
    Bluestone, Jeffrey A.
    Buckner, Jane H.
    Fitch, Mark
    Gitelman, Stephen E.
    Gupta, Shipra
    Hellerstein, Marc K.
    Herold, Kevan C.
    Lares, Angela
    Lee, Michael R.
    Li, Kelvin
    Liu, Weihong
    Long, S. Alice
    Masiello, Lisa M.
    Vinh Nguyen
    Putnam, Amy L.
    Rieck, Mary
    Sayre, Peter H.
    Tang, Qizhi
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (315)